<DOC>
	<DOC>NCT00169442</DOC>
	<brief_summary>To assess the immune memory following primary vaccination of DTPw-HBV/Hib vaccine and to assess immunogenicity and reactogenicity of a booster dose given at 15 - 18 months of age.</brief_summary>
	<brief_title>Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno &amp; Reacto of a Booster Dose Given in Infants</brief_title>
	<detailed_description>- Subjects who received DTPw-HBV/Hib in the primary vaccination without HBV at birth will be randomised (1:3 ratio) to receive either: Plain PRP at 10 months of age followed by DTPw-HBV at 15-18 months of age or DTPw-HBV/Hib at 15-18 months of age. - Subjects who received DTPw-HBV + Hib in the primary vaccination without HBV at birth will receive DTPw-HBV + Hib as a booster. - Subjects who received DTPw-HBV/Hib in the primary vaccination with HBV at birth will receive DTPw-HBV/Hib vaccine as a booster.</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Inclusion criteria: For subjects receiving Plain PRP followed by DTPwHBV: Male or female infant, 10 to 11 months of age, who previously completed the threedose primary vaccination course with the DTPwHBV/Hib vaccine. For subjects receiving DTPwHBV/Hib or DTPwHBV + Hib: Male or female infant, 1518 months of age, who previously completed the threedose primary vaccination course with the DTPwHBV/Hib vaccine. For all subjects: Subjects who the investigator believes that their parent/guardian can and will comply with the requirements of the protocol. Free of obvious health problems as established by medical history and clinical examination Exclusion criteria: Use of any investigational or nonregistered product other than the study vaccine(s) within 30 days preceding administration of the study vaccine, or planned use during the study period. Chronic administration of immunosuppressants or other immunemodifying drugs within six months prior to administration of the study vaccine. Planned administration/administration of a vaccine not foreseen by the study protocol starting 30 days before and ending 30 days after administration of the study vaccine with the exception of oral polio vaccine.</criteria>
	<gender>All</gender>
	<minimum_age>10 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>